APPLICATION NUMBER:

203045Orig1s000

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
EXCLUSIVITY SUMMARY

NDA # 203045       SUPPL #          HFD # 530

Trade Name      ISENTRESS

Generic Name     raltegravir potassium

Applicant Name   Merck Sharp & Dohme Corp.

Approval Date, If Known

PART I   IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, and all efficacy
supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to
one or more of the following questions about the submission.

   a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement?  
      YES ☒    NO ☐

      If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8

      505(b)(1)

   c) Did it require the review of clinical data other than to support a safety claim or change in
      labeling related to safety?  (If it required review only of bioavailability or bioequivalence
      data, answer "no.")
      YES ☒    NO ☐

      If your answer is "no" because you believe the study is a bioavailability study and, therefore,
      not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your
      reasons for disagreeing with any arguments made by the applicant that the study was not
      simply a bioavailability study.

      N/A

      If it is a supplement requiring the review of clinical data but it is not an effectiveness
      supplement, describe the change or claim that is supported by the clinical data:

      N/A
d) Did the applicant request exclusivity?  

YES ☒  NO ☐

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

3

e) Has pediatric exclusivity been granted for this Active Moiety?  

YES ☐  NO ☒

If the answer to the above question in YES, is this approval a result of the studies submitted in response to the Pediatric Written Request?

N/A

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS AT THE END OF THIS DOCUMENT.

2. Is this drug product or indication a DESI upgrade?  

YES ☐  NO ☒

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II  FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES  
(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

YES ☒  NO ☐

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(#(s)).
2. Combination product.

If the product contains more than one active moiety (as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES ☐ NO ☐

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA#

NDA#

NDA#

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. (Caution: The questions in part II of the summary should only be answered “NO” for original approvals of new molecular entities.)

IF “YES,” GO TO PART III.

PART III THREE-YEAR EXCLUSIVITY FOR NDAs AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of
summary for that investigation.

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES ☒ NO ☐

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

N/A

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES ☒ NO ☐

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES ☐ NO ☒

If yes, explain:

N/A

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES ☐ NO ☒
If yes, explain:

N/A

(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

IMPAACT P1066/Merck PN022: "A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Raltegravir (Isentress™, MK- 0518) in HIV-1 Infected Children and Adolescents."

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not re-demonstrate something the agency considers to have been demonstrated in an already approved application.

   a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

   Investigation #1
   YES ☐ NO ☑

   Investigation #2
   YES ☐ NO ☐

   If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

   N/A

   b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

   Investigation #1
   YES ☐ NO ☑

   Investigation #2
   YES ☐ NO ☐
If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

N/A

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):

IMPAACT P1066/Merck PN022: "A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Raltegravir (Isentress™, MK-0518) in HIV-1 Infected Children and Adolescents."

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

<table>
<thead>
<tr>
<th>Investigation #1</th>
<th>IND # 69928</th>
<th>YES ☒</th>
<th>NO ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigation #1</th>
<th>IND # 77787</th>
<th>YES ☒</th>
<th>NO ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigation #2</th>
<th>IND #</th>
<th>YES ☒</th>
<th>NO ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1

YES ☑️

NO ☐

Explain: Applicant provided certification in NDA regarding investigation conducted under IND 77787

Investigation #2

YES ☐

NO ☐

Explain:

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

YES ☐

NO ☑️

If yes, explain:

Name of person completing form: Elizabeth Thompson, M.S.
Title: Regulatory Project Manager
Date: August 5, 2011

Name of Office/Division Director signing form: Jeffrey Murray, M.D., M.P.H.
Title: Deputy Division Director

Form OGD-011347; Revised 05/10/2004; formatted 2/15/05
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
12/05/2011

JEFFREY S MURRAY
12/06/2011
### ACTION PACKAGE CHECKLIST

#### APPLICATION INFORMATION

<table>
<thead>
<tr>
<th>NDA #</th>
<th>203045</th>
<th>NDA Supplement #</th>
<th>If NDA, Efficacy Supplement Type:</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLA #</td>
<td></td>
<td>BLA STN #</td>
<td></td>
</tr>
</tbody>
</table>

| Proprietary Name: | ISENTRESS |
| Established/Proper Name: | raltegravir |
| Dosage Form: | 25 mg and 100 mg chewable tablets |

| Applicant: | Merck Sharp & Dohme |
| Agent for Applicant (if applicable): | |

| RPM: | Elizabeth Thompson |
| Division: | DAVP |

#### NDAs:

| NDA Application Type: | ☑ 505(b)(1) | ☑ 505(b)(2) |
| Efficacy Supplement: | ☑ 505(b)(1) | ☑ 505(b)(2) |

(A supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2). Consult page 1 of the 505(b)(2) Assessment or the Appendix to this Action Package Checklist.)

#### 505(b)(2) ORIGANDS AND 505(b)(2) NDA SUPPLEMENTS:

Listed drug(s) relied upon for approval (include NDA #(s) and drug name(s)):

Provide a brief explanation of how this product is different from the listed drug.

- [ ] This application relies on literature.
- [ ] This application relies on a final OTC monograph.
- [ ] Other (explain)

Two months prior to each action, review the information in the 505(b)(2) Assessment and submit the draft to CDER OND IO for clearance. Finalize the 505(b)(2) Assessment at the time of the approval action.

**On the day of approval**, check the Orange Book again for any new patents or pediatric exclusivity.

- [ ] No changes
- [ ] Updated

**Date of check:**

If pediatric exclusivity has been granted or the pediatric information in the labeling of the listed drug changed, determine whether pediatric information needs to be added to or deleted from the labeling of this drug.

#### Actions

- Proposed action
- User Fee Goal Date is December 30, 2011
- Previous actions (specify type and date for each action taken) ☑ None

- [ ] AP
- [ ] TA
- [ ] CR

- [ ] Received

---

1 The **Application Information** section is (only) a checklist. The **Contents of Action Package** section (beginning on page 5) lists the documents to be included in the Action Package.

Reference ID: 3061756

Version: 8/29/11
**Application Characteristics**

<table>
<thead>
<tr>
<th>Review priority:</th>
<th></th>
<th>Standard</th>
<th>Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical classification (new NDAs only):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fast Track</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rolling Review</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orphan drug designation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rx-to-OTC full switch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rx-to-OTC partial switch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct-to-OTC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDAs: Subpart I</td>
<td></td>
<td>Accelerated approval (21 CFR 314.510)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restricted distribution (21 CFR 314.520)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Approval based on animal studies</td>
<td></td>
</tr>
<tr>
<td>BLAs: Subpart E</td>
<td></td>
<td>Accelerated approval (21 CFR 601.41)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restricted distribution (21 CFR 601.42)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Approval based on animal studies</td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td>Submitted in response to a PMR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Submitted in response to a PMC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Submitted in response to a Pediatric Written Request</td>
<td></td>
</tr>
<tr>
<td>REMS:</td>
<td></td>
<td>MedGuide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Communication Plan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ETASU</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>REMS not required</td>
<td></td>
</tr>
</tbody>
</table>

- **BLAs only:** Ensure RMS-BLA Product Information Sheet for TBP and RMS-BLA Facility Information Sheet for TBP have been completed and forwarded to OPI/OBI/DRM (Vicky Carter)
  - Yes, dates

- **BLAs only:** Is the product subject to official FDA lot release per 21 CFR 610.2 (approvals only)
  - Yes
  - No

- **Public communications (approvals only)**
  - Office of Executive Programs (OEP) liaison has been notified of action
    - Yes
    - No
  - Press Office notified of action (by OEP)
    - Yes
    - No
  - Indicate what types (if any) of information dissemination are anticipated
    - None
    - HHS Press Release
    - FDA Talk Paper
    - CDER Q&As
    - Other Information Advisory

---

2 Answer all questions in all sections in relation to the pending application, i.e., if the pending application is an NDA or BLA supplement, then the questions should be answered in relation to that supplement, not in relation to the original NDA or BLA. For example, if the application is a pending BLA supplement, then a new RMS-BLA Product Information Sheet for TBP must be completed.
## Exclusivity

- **Is approval of this application blocked by any type of exclusivity?**
  - ☒ No ☐ Yes

- **NDAs and BLAs: Is there existing orphan drug exclusivity for the “same” drug or biologic for the proposed indication(s)? Refer to 21 CFR 316.3(b)(13) for the definition of “same drug” for an orphan drug (i.e., active moiety). This definition is NOT the same as that used for NDA chemical classification.**
  - ☐ No ☑ Yes
  - If yes, NDA/BLA # and date exclusivity expires:

- **(b)(2) NDAs only: Is there remaining 5-year exclusivity that would bar effective approval of a 505(b)(2) application? (Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)**
  - ☐ No ☑ Yes
  - If yes, NDA # and date exclusivity expires:

- **(b)(2) NDAs only: Is there remaining 3-year exclusivity that would bar effective approval of a 505(b)(2) application? (Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)**
  - ☐ No ☑ Yes
  - If yes, NDA # and date exclusivity expires:

- **(b)(2) NDAs only: Is there remaining 6-month pediatric exclusivity that would bar effective approval of a 505(b)(2) application? (Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)**
  - ☐ No ☑ Yes
  - If yes, NDA # and date exclusivity expires:

- **NDAs only: Is this a single enantiomer that falls under the 10-year approval limitation of 505(u)? (Note that, even if the 10-year approval limitation period has not expired, the application may be tentatively approved if it is otherwise ready for approval.)**
  - ☐ No ☑ Yes
  - If yes, NDA # and date 10-year limitation expires:

## Patent Information (NDAs only)

- **Patent Information:**
  - Verify that form FDA-3542a was submitted for patents that claim the drug for which approval is sought. If the drug is an old antibiotic, skip the Patent Certification questions.
  - ☐ Verified ☑ Not applicable because drug is an old antibiotic.

- **Patent Certification [505(b)(2) applications]:**
  - Verify that a certification was submitted for each patent for the listed drug(s) in the Orange Book and identify the type of certification submitted for each patent.
  - 21 CFR 314.50(j)(1)(i)(A)
  - ☐ Verified
  - 21 CFR 314.50(j)(1)
  - ☐ (ii) ☐ (iii)

- **[505(b)(2) applications]** If the application includes a **paragraph III certification**, it cannot be approved until the date that the patent to which the certification pertains expires (but may be tentatively approved if it is otherwise ready for approval).
  - ☐ No paragraph III certification
  - Date patent will expire

- **[505(b)(2) applications] For each **paragraph IV certification**, verify that the applicant notified the NDA holder and patent owner(s) of its certification that the patent(s) is invalid, unenforceable, or will not be infringed (review documentation of notification by applicant and documentation of receipt of notice by patent owner and NDA holder). (If the application does not include any paragraph IV certifications, mark “N/A” and skip to the next section below (Summary Reviews)).**
  - ☐ N/A (no paragraph IV certification)
  - ☐ Verified
For each paragraph IV certification, based on the questions below, determine whether a 30-month stay of approval is in effect due to patent infringement litigation.

Answer the following questions for each paragraph IV certification:

1. Have 45 days passed since the patent owner’s receipt of the applicant’s notice of certification?
   - **Yes**
   - **No**
   
   (Note: The date that the patent owner received the applicant’s notice of certification can be determined by checking the application. The applicant is required to amend its 505(b)(2) application to include documentation of this date (e.g., copy of return receipt or letter from recipient acknowledging its receipt of the notice) (see 21 CFR 314.52(e)).)

   **If “Yes,” skip to question (4) below. If “No,” continue with question (2).**

2. Has the patent owner (or NDA holder, if it is an exclusive patent licensee) submitted a written waiver of its right to file a legal action for patent infringement after receiving the applicant’s notice of certification, as provided for by 21 CFR 314.107(f)(3)?
   - **Yes**
   - **No**

   **If “Yes,” there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip the rest of the patent questions.**

   **If “No,” continue with question (3).**

3. Has the patent owner, its representative, or the exclusive patent licensee filed a lawsuit for patent infringement against the applicant?
   - **Yes**
   - **No**

   (Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2)).)

   **If “No,” the patent owner (or NDA holder, if it is an exclusive patent licensee) has until the expiration of the 45-day period described in question (1) to waive its right to bring a patent infringement action or to bring such an action. After the 45-day period expires, continue with question (4) below.**

   **If “Yes,” continue with question (5).**

4. Did the patent owner (or NDA holder, if it is an exclusive patent licensee) submit a written waiver of its right to file a legal action for patent infringement within the 45-day period described in question (1), as provided for by 21 CFR 314.107(f)(3)?
   - **Yes**
   - **No**

   **If “Yes,” there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).**

   **If “No,” continue with question (5).**
(5) Did the patent owner, its representative, or the exclusive patent licensee bring suit against the (b)(2) applicant for patent infringement within 45 days of the patent owner’s receipt of the applicant’s notice of certification?

(Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(i)(2)). If no written notice appears in the NDA file, confirm with the applicant whether a lawsuit was commenced within the 45-day period).

If “No,” there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).

If “Yes,” a stay of approval may be in effect. To determine if a 30-month stay is in effect, consult with the OND ADRA and attach a summary of the response.

## CONTENTS OF ACTION PACKAGE

- Copy of this Action Package Checklist
  - Included

### Officer/Employee List

- List of officers/employees who participated in the decision to approve this application and consented to be identified on this list (approvals only)
  - Included

- Documentation of consent/non-consent by officers/employees
  - Included

### Action Letters

- Copies of all action letters (including approval letter with final labeling)
  - Action(s) and date(s)
    - Approval: December 21, 2011

### Labeling

- Package Insert (write submission/communication date at upper right of first page of PI)
  - Most recent draft labeling. If it is division-proposed labeling, it should be in track-changes format.
    - December 20, 2011
  - Original applicant-proposed labeling
    - June 30, 2011
  - Example of class labeling, if applicable
    - N/A

---

3 Fill in blanks with dates of reviews, letters, etc.

Reference ID: 3061756
<table>
<thead>
<tr>
<th>Medication Guide/Patient Package Insert/Instructions for Use/Device Labeling (write submission/communication date at upper right of first page of each piece)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Most-recent draft labeling. If it is division-proposed labeling, it should be in track-changes format.</strong></td>
</tr>
<tr>
<td>December 20, 2011</td>
</tr>
<tr>
<td><strong>Original applicant-proposed labeling</strong></td>
</tr>
<tr>
<td>June 30, 2011</td>
</tr>
<tr>
<td><strong>Example of class labeling, if applicable</strong></td>
</tr>
<tr>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Labels (full color carton and immediate-container labels) (write submission/communication date on upper right of first page of each submission)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Most-recent draft labeling</strong></td>
</tr>
<tr>
<td>December 20, 2011</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Proprietary Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acceptability/non-acceptability letter(s) (indicate date(s))</strong></td>
</tr>
<tr>
<td>N/A</td>
</tr>
<tr>
<td><strong>Review(s) (indicate date(s))</strong></td>
</tr>
<tr>
<td>N/A</td>
</tr>
<tr>
<td><strong>Ensure that both the proprietary name(s), if any, and the generic name(s) are listed in the Application Product Names section of DARRTS, and that the proprietary/trade name is checked as the 'preferred' name.</strong></td>
</tr>
<tr>
<td>RPM 8-9-2011 and 12-21-2011</td>
</tr>
<tr>
<td>DMEPA 11-15-2011</td>
</tr>
<tr>
<td>DMPP 12-1-2011</td>
</tr>
<tr>
<td>DPP/DDTCP 11-21-2011</td>
</tr>
<tr>
<td>SEALD</td>
</tr>
<tr>
<td>CSS</td>
</tr>
<tr>
<td>Other reviews</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Labeling reviews (indicate dates of reviews and meetings)</th>
</tr>
</thead>
</table>

### Administrative / Regulatory Documents

| Administrative Reviews (e.g., RPM Filing Review/Memo of Filing Meeting) (indicate date of each review) |
| August 18, 2011 |
| All NDA (b)(2) Actions: Date each action cleared by (b)(2) Clearance Cntr |
| NDA (b)(2) Approvals Only: 505(b)(2) Assessment (indicate date) |
| Not a (b)(2) |
| Not a (b)(2) |
| NDAs only: Exclusivity Summary (signed by Division Director) |
| Included |
| Application Integrity Policy (AIP) Status and Related Documents [http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm](http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm) |

### Pediatrics (approvals only)

| Date reviewed by PeRC  |
| October 12, 2011 |
| If PeRC review not necessary, explain: |
| Pediatric Page/Record (approvals only, must be reviewed by PERC before finalized) |
| Included |

---

4 Filing reviews for scientific disciplines should be filed behind the respective discipline tab.

Reference ID: 3061756
### Decisional and Summary Memos

- **Office Director Decisional Memo (indicate date for each review)**: None
- **Division Director Summary Review (indicate date for each review)**: None
- **Cross-Discipline Team Leader Review (indicate date for each review)**: None, 12-19-2011
- **PMR/PMC Development Templates (indicate total number)**: None, 1

### Clinical Information

- **Clinical Reviews**
  - Clinical Team Leader Review(s) (indicate date for each review)
  - Clinical review(s) (indicate date for each review)
  - Social scientist review(s) (if OTC drug) (indicate date for each review): None

- **Financial Disclosure reviews(s) or location/date if addressed in another review**
  - See Clinical Review

- **Clinical reviews from immunology and other clinical areas/divisions/Centers (indicate date of each review)**: None

- **Controlled Substance Staff review(s) and Scheduling Recommendation (indicate date of each review)**: Not applicable

- **Risk Management**
  - REMS Documents and Supporting Statement (indicate date of submission(s))
  - REMS Memo(s) and letter(s) (indicate date(s))
  - Risk management review(s) and recommendations (including those by OSE and CSS) (indicate date of each review and indicate location/date if incorporated into another review): None, N/A

---

5 Filing reviews should be filed with the discipline reviews.
<table>
<thead>
<tr>
<th><strong>Clinical Microbiology</strong></th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Microbiology Team Leader Review(s) (indicate date for each review)</strong></td>
<td>None</td>
</tr>
<tr>
<td>Clinical Microbiology Review(s) (indicate date for each review)</td>
<td>None 12-7-2011</td>
</tr>
<tr>
<td><strong>Biostatistics</strong></td>
<td>None</td>
</tr>
<tr>
<td>Statistical Division Director Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>Statistical Team Leader Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>Statistical Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td><strong>Clinical Pharmacology</strong></td>
<td>None</td>
</tr>
<tr>
<td>Clinical Pharmacology Division Director Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>Clinical Pharmacology Team Leader Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>Clinical Pharmacology review(s) (indicate date for each review)</td>
<td>None 12-6-2011</td>
</tr>
<tr>
<td><strong>DSI Clinical Pharmacology Inspection Review Summary (include copies of DSI letters)</strong></td>
<td>None 11-23-2011</td>
</tr>
<tr>
<td><strong>Nonclinical</strong></td>
<td>None</td>
</tr>
<tr>
<td>Pharmacology/Toxicology Discipline Reviews</td>
<td></td>
</tr>
<tr>
<td>• ADP/T Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>• Supervisory Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>• Pharm/tox review(s), including referenced IND reviews (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>• Review(s) by other disciplines/divisions/Centers requested by P/T reviewer (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>• Statistical review(s) of carcinogenicity studies (indicate date for each review)</td>
<td>No carc</td>
</tr>
<tr>
<td>• ECAC/CAC report/memo of meeting</td>
<td>None Included in P/T review, page</td>
</tr>
<tr>
<td>• DSI Nonclinical Inspection Review Summary (include copies of DSI letters)</td>
<td>None requested</td>
</tr>
<tr>
<td><strong>Product Quality</strong></td>
<td>None</td>
</tr>
<tr>
<td>• ONDQA/OBP Division Director Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>• Branch Chief/Team Leader Review(s) (indicate date for each review)</td>
<td>None</td>
</tr>
<tr>
<td>• Product quality review(s) including ONDQA biopharmaceutics reviews (indicate date for each review)</td>
<td>None CMC Review: 12-5-2011 ONDQA Biopharm: 12-7-2011</td>
</tr>
<tr>
<td><strong>Microbiology Reviews</strong></td>
<td></td>
</tr>
<tr>
<td>• NDAs: Microbiology reviews (sterility &amp; pyrogenicity) (OPS/NDMS) (indicate date of each review)</td>
<td>Not needed</td>
</tr>
<tr>
<td>• BLAS: Sterility assurance, microbiology, facilities reviews (OMPQ/MAPCB/BMT) (indicate date of each review)</td>
<td></td>
</tr>
<tr>
<td>• Reviews by other disciplines/divisions/Centers requested by CMC/quality reviewer (indicate date of each review)</td>
<td>None</td>
</tr>
<tr>
<td>Environmental Assessment (check one) (original and supplemental applications)</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>✗ Categorical Exclusion <em>indicate review date</em> (all original applications and all efficacy supplements that could increase the patient population)</td>
<td>12-5-2011</td>
</tr>
<tr>
<td>☐ Review &amp; FONSI <em>indicate date of review</em></td>
<td></td>
</tr>
<tr>
<td>☐ Review &amp; Environmental Impact Statement <em>indicate date of each review</em></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Facilities Review/Inspection</th>
</tr>
</thead>
<tbody>
<tr>
<td>✗ NDAs: Facilities inspections (include EER printout) <em>date completed must be within 2 years of action date</em> (only original NDAs and supplements that include a new facility or a change that affects the manufacturing sites)*</td>
</tr>
<tr>
<td>Date completed: 10-13-2011</td>
</tr>
<tr>
<td>☐ Acceptable</td>
</tr>
<tr>
<td>☐ Withhold recommendation</td>
</tr>
<tr>
<td>☐ Not applicable</td>
</tr>
<tr>
<td>☐ BLAs: TB-EER <em>date of most recent TB-EER must be within 30 days of action date</em> (original and supplemental BLAs)</td>
</tr>
<tr>
<td>Date completed:</td>
</tr>
<tr>
<td>☐ Acceptable</td>
</tr>
<tr>
<td>☐ Withhold recommendation</td>
</tr>
<tr>
<td>☐ Complet ed</td>
</tr>
<tr>
<td>☐ Requested</td>
</tr>
<tr>
<td>☐ Not yet requested</td>
</tr>
<tr>
<td>✗ Not needed (per review)</td>
</tr>
</tbody>
</table>

---

6 I.e., a new facility or a change in the facility, or a change in the manufacturing process in a way that impacts the Quality Management Systems of the facility.
Appendix to Action Package Checklist

An NDA or NDA supplemental application is likely to be a 505(b)(2) application if:

1. It relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application.

2. Or it relies for approval on the Agency's previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval.

3. Or it relies on what is "generally known" or "scientifically accepted" about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean any reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations); OTC monograph deviations(see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

1. The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies).

2. And no additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness for the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application.

3. And all other “criteria” are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

1. Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2).

2. Or the applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement.

3. Or the applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your ODE’s ADRA.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
12/21/2011

Reference ID: 3061756
From: Thompson, Elizabeth
Sent: Monday, December 05, 2011 11:44 AM
To: Frontling, Robert A.
Cc: Thompson, Elizabeth
Subject: Isentress ped: updated labeling
Importance: High

Bob-

Attached please find the Division's next round of labeling comments/revisions for the Isentress ped applications.

1. Please note that we are recommending Merck add aspartame to the list of inactive ingredients. While there is not requirement for this, we feel this may avoid questions if a physician/patient sees the warning about phenylalanine, and then looks at the list of inactive ingredients. Please let us know if you agree (see comments in labels).

2. Also note that extensive revisions were made to the Patient Information to include reformatting and patient friendly language to promote readability and comprehension. We deleted underlining and italicizing and recommend bolding and bullets to call attention to important information. This newly revised Patient Information follows the formatting of other HIV labels in the Division.

We should have our PMR/PMC's for you soon as well.

Regards,

Beth

Elizabeth Thompson, M.S.
LT, U.S. Public Health Service
Regulatory Project Manager
FDA/CDER/OND/DAVP
10903 New Hampshire Avenue
Bldg #22, Rm 6324
Silver Spring, MD 20993
301-796-0824 (office); 301-796-9883 (fax)
elizabeth.thompson@fda.hhs.gov

32 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

Reference ID: 3053796
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
12/05/2011
NDA 203045

INFORMATION REQUEST

Merck Sharp & Dohme Corp.
Attention: Robert A. Fromling, Ph.D.
Director, Worldwide Regulatory Affairs
126 E. Lincoln Avenue
P.O. Box 2000, RY 33-212
Rahway, NJ 07065-0900

Dear Dr. Fromling:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ISENTRESS (raltegravir potassium) Chewable Tablets.

We are reviewing the Chemistry, Manufacturing and Controls sections of your submission and have the following comments and information requests. In order to continue our evaluation of your NDA, we request a prompt written response by December 1, 2011.

1. The raltegravir drug substance specifications in the NDA has an acceptance criteria of (b)(4) for particle size. Your communication dated August 25, 2011, Response #1 states, (b)(4)

Therefore, please revise the particle size specification to (b)(4) and provide an updated drug substance specification table.

2. (b)(4)

To facilitate prompt review of your response, please also provide an electronic courtesy copy of your response to both Jeannie David, Regulatory Project Manager in the Office of New Drug Quality Assessment (Jeannie.David@fda.hhs.gov), and Elizabeth Thompson, Regulatory Project Manager the Office of New Drugs (Elizabeth.Thompson@fda.hhs.gov).

If you have any questions regarding this CMC letter, call Jeannie David at (301) 796-4247.
Sincerely,

*See appended electronic signature page*

Rapti D. Madurawe, Ph.D.
Branch Chief, Branch V
Division of New Drug Quality Assessment II
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAPTI D MADURAWE
11/22/2011
Attached please find a copy of the Division's recommended labeling proposals for the Package Insert and for carton/container labeling. We are still working on the Patient Information and will send our revisions when that is completed. Please let me know if you have any questions.

Carton/Container Labeling:

- Please revise the statement, [obscured], to read, 'For Pediatric Patients 2 to less than 12 Years of Age'.

Regards,

Beth

Elizabeth Thompson, M.S.
LT, U.S. Public Health Service
Regulatory Project Manager
FDA/CDER/OND/DAVP
10903 New Hampshire Avenue
Bldg #22, Rm 6324
Silver Spring, MD 20993
301-796-0824 (office); 301-796-9883 (fax)
elizabeth.thompson@fda.hhs.gov

24 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
11/22/2011
Please refer to your New Drug Application (NDA) and to your Supplemental NDA dated and received June 30, 2011, for Isentress (raltegravir potassium) chewable tablets and Isentress (raltegravir potassium) tablets. We have the following comments and request for information.

- Please clarify why there are some subjects in all cohorts with two different entries in the sparse PK dataset. In all such cases the 2nd entry includes a different dose, body weight and raltegravir concentration for the same time point. For example, in Cohort 2, subject 8500413K has two entries, each with a different dose, weight and concentration reported for Weeks 4, 8, 12 and 24. These two entries appear to correspond to what is designated as Step 1 and 2 in other datasets. In addition, many of these subjects appear to have sparse PK data for the final proposed dose, but are not included in the non-model based PK analysis. Please explain the criteria for inclusion or exclusion of sparse PK data in the analysis.
PLEASE REPLY BY EMAIL (elizabeth.thompson@fda.hhs.gov) and (Karen.Winesotck@fda.HHS.gov) to confirm receipt. If you have any questions regarding the contents of this correspondence, please contact Elizabeth Thompson by email or phone (301-796 0824).

{See appended electronic signature page}

____________________________
Elizabeth Thompson, M.S.
LT, USPHS
Regulatory Project Manager
Division of Antiviral Products
Center for Drug Evaluation and Research
Food and Drug Administration
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KAREN D WINESTOCK
11/10/2011
Please refer to your New Drug Application (NDA) dated and received June 30, 2011, for Isentress (raltegravir potassium) chewable tablets. We have the following comments and request for information.

Please provide clarifications for the following:

1. **Disposition of Subjects:**
   - We note in Table 14.2 that for Cohort I, there is a total of 4 subjects who did not complete the trial to Week 48 (i.e. 3 subjects did not complete to Week 24, and an additional subject did not complete to Week 48). Please provide the reasons for the discontinuations, at what time point each discontinued the study drug/trial, and what each subject's HIV RNA was at the time of discontinuation.
   - Please provide additional information for the 2 'virologic failure' subjects, 1 subject each in Cohorts I and III. Specifically, discuss if the failure was due to 'rebound' or 'never suppressed'.

2. **Efficacy Analysis:**
   - Please note that the Division will calculate efficacy outcomes based on the snapshot algorithm. In addition, regardless of which algorithm used, the denominator used to calculate the proportion of subjects with HIV-RNA <50 or <400 copies/mL at Week
24 or 48 is always the ITT population. Therefore, the response rate for Cohort 1 will be based on N=59. Similarly, the response rate for Cohort IIB will be based on N=13.

- Please corroborate the denominators you have used for your efficacy calculations, specifically those noted in Table 11-2 from the MK-0518 CSR (denominator of 56 for Cohort I, and 11 for Cohort IIB).

- Lastly, please provide information about any changes in background regimens (OBT) for those subjects who were considered responders (<50 and/or <400 copies/mL) at Weeks 24 and 48.

PLEASE REPLY BY EMAIL (elizabeth.thompson@fda.hhs.gov) to confirm receipt. If you have any questions regarding the contents of this correspondence, please contact me by email or phone (301-796 0824).

{See appended electronic signature page}

Elizabeth Thompson, M.S.
LT, USPHS
Regulatory Project Manager
Division of Antiviral Products
Center for Drug Evaluation and Research
Food and Drug Administration
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
09/29/2011
Dear Dr. Fromtling:

Please refer to your New Drug Application (NDA) dated June 30, 2011, received June 30, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, for ISENTRESS (raltegravir potassium) chewable tablets.

We have completed our filing review and have determined that your application is sufficiently complete to permit a substantive review. Therefore, in accordance with 21 CFR 314.101(a), this application is considered filed 60 days after the date we received your application. The review classification for this application is Priority. Therefore, the user fee goal date is December 30, 2011.

We are reviewing your application according to the processes described in the Guidance for Review Staff and Industry: Good Review Management Principles and Practices for PDUFA Products. Therefore, we have established internal review timelines as described in the guidance, which includes the timeframes for FDA internal milestone meetings (e.g., filing, planning, midcycle, team and wrap-up meetings). Please be aware that the timelines described in the guidance are flexible and subject to change based on workload and other potential review issues (e.g., submission of amendments). We will inform you of any necessary information requests or status updates following the milestone meetings or at other times, as needed, during the process.

If major deficiencies are not identified during the review, we plan to communicate proposed labeling and, if necessary, any postmarketing requirement/commitment requests by December 9, 2011.

At this time, we are notifying you that, we have not identified any potential review issues. Please note that our filing review is only a preliminary evaluation of the application and is not indicative of deficiencies that may be identified during our review.
We request that you submit the following information:

CLINICAL
1. Please provide a brief rationale for assuming the applicability of foreign data to the U.S. population, or to the practice of medicine in the U.S.

CMC

CLINICAL PHARMACOLOGY
3. Please re-submit the following bioanalytical, intensive pharmacokinetic, and population pharmacokinetic reports using a different font such as Arial or Times New Roman, as the current font is unreadable:
   a. Report title: Quantitative Analysis of Raltegravir Extracted from Human Plasma from Patients Enrolled into P1066 (Appendix 16.1.11.10)
   b. Report title: Intensive Pharmacokinetic Analyses of Raltegravir Concentration-Time Results from P1066 (Appendix 16.1.11.11)
   c. Report title: Population Pharmacokinetic Analyses of Raltegravir Concentration-time Results from P0166 (Appendix 16.1.11.12)

During our preliminary review of your submitted labeling, we have identified the following labeling format issues:

1. In Highlights, under USE IN SPECIFIC POPULATIONS, state “Pregnancy registry available (8.1).” DO NOT include the telephone number or information on how to enroll patients in the study under Highlights. This information should appear under the Pregnancy subsection (8.1) in the FPI.

2. The corresponding new or modified text in the FPI sections listed under Recent Major Changes must be marked with a vertical line (“margin mark”) on the left edge. Please re-check your SPL to be sure that this displays properly.

3. The Patient Counseling Information section (Section 17) should be revised to include the statement “See FDA-approved patient labeling (Patient Information”).

4. In your Patient Information section, please delete [b][4]
   Only “Patient Information” should be listed as the title.

We request that you resubmit labeling that addresses these issues by September 12, 2011. The resubmitted labeling will be used for further labeling discussions.
Please respond only to the above requests for information. While we anticipate that any response submitted in a timely manner will be reviewed during this review cycle, such review decisions will be made on a case-by-case basis at the time of receipt of the submission.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have not addressed how you plan to fulfill this requirement for pediatric patients from 0 to less than 2 years of age and for pediatric patients from 12 to 18 years of age. Within 30 days of the date of this letter, please submit a partial waiver request and a pediatric development plan for the pediatric age groups not covered by the partial waiver request. All waiver requests must include supporting information and documentation. A pediatric drug development plan must address the indication(s) proposed in this application.

We also note that you have submitted pediatric studies with this application for pediatric patients ages 2 to 11. Once the review of this application is complete we will notify you whether you have fulfilled the pediatric study requirement for this age group.

If you have any questions, call Elizabeth Thompson, M.S., Regulatory Project Manager, at (301) 796-0824.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY S MURRAY
08/24/2011
INFORMATION REQUEST

Merck Sharp & Dohm Corp.
Attention: Robert A. Fromtling, Ph.D.
Director Worldwide Regulatory Affairs
126 E. Lincoln Avenue
P. O. Box 2000, RY 33-212
Rahway, NJ 07065-0900

Dear Dr. Fromtling:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Isentress® (raltegravir potassium) chewable tablets, 25 mg, 100 mg.

We are reviewing the Chemistry, Manufacturing and Controls sections of your submission and have the following comments and information requests. We request your official written response by August 26, 2011.

1. Please clarify if the mean particle range of is a specification requirement for the drug substance during manufacturing of the chewable tablet.

2. Please clarify if the discoloration observed is related to the presence of iron oxide in the product. Provide information studied on this observation, if available.

3. Please provide any available stability updates on the “bridging stability batches” (containing increased desiccant) by August 26, 2011.

4. Please provide a statistical analysis of all available stability data for the package in HDPE bottles to support the proposed shelf life. Please include any update in the analysis if available.

5. (b) (4)
6. Please justify the lack of microbiological purity testing in the drug product specifications during shelf life in Section 3.2.P.5.6. The justification should include consideration of the tablets upon storage, risk of microbial contamination during processing and from incoming materials, and current available data on microbial purity. Please also refer to question 5 above.

If appropriate, please propose and include a protocol for microbial purity testing for the first three commercial batches of tablets placed on stability and for the annual stability monitoring protocol (Section 3.2.P.8.2). The proposed frequency of testing should be based on the level of risk of microbial contamination and growth, as described in USP <1112> and ICH Q6A Decision Tree #8. Please update Section 3.2.P.5.1 and 3.2.P.8.1 accordingly to reflect microbiological purity method and testing criteria on shelf life.

7. Provide a sample of each package configuration if available.

To facilitate prompt review of your response, please also provide an electronic courtesy copy of your response to both Jeannie David, Regulatory Project Manager in the Office of New Drug Quality Assessment (Jeannie.David@fda.hhs.gov), and Elizabeth Thompson, Regulatory Project Manager the Office of New Drugs (Elizabeth.Thompson@fda.hhs.gov).

If you have any questions regarding this CMC letter, contact Jeannie David, Regulatory Project Manager, at (301) 796-4247, or jeannie.david@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Rapti D. Madurawe, Ph.D.
Branch Chief, Branch V
Division of New Drug Quality Assessment II
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-----------------------------------------------
RAPTI D MADURAWE
08/05/2011
NDA 203045

Merck Sharp & Dohme Corp.
Attention: Robert A. Fromtling, Ph.D.
Director, Worldwide Regulatory Affairs
126 E. Lincoln Avenue
P.O. Box 2000, RY 33-212
Rahway, NJ 07065-0900

Dear Dr. Fromtling:

We have received your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Name of Drug Product: ISENTRESS (raltegravir potassium) chewable tablets

Date of Application: June 30, 2011

Date of Receipt: June 30, 2011

Our Reference Number: NDA 203045

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on August 29, 2011, in accordance with 21 CFR 314.101(a).

If you have not already done so, promptly submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Failure to submit the content of labeling in SPL format may result in a refusal-to-file action under 21 CFR 314.101(d)(3). The content of labeling must conform to the content and format requirements of revised 21 CFR 201.56-57.

You are also responsible for complying with the applicable provisions of sections 402(i) and 402(j) of the Public Health Service Act (PHS Act) [42 USC §§ 282 (i) and (j)], which was amended by Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA) (Public Law No, 110-85, 121 Stat. 904).
The NDA number provided above should be cited at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

    Food and Drug Administration
    Center for Drug Evaluation and Research
    Division of Antiviral Products
    5901-B Ammendale Road
    Beltsville, MD 20705-1266

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, please see http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073080.htm.

If you have any questions, call Elizabeth Thompson, Regulatory Project Manager, at (301) 796-0824.

Sincerely,

    {See appended electronic signature page}

Elizabeth Thompson, M.S.
LT, U.S. Public Health Service
Regulatory Project Manager
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
07/11/2011